Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Silverman Chiropractic and Rehabilitation Takes on a Board Certified Pain Management Doctor


Silverman Chiropractic and Rehabilitation clinic adds a board certified pain management doctor who specializes in pain management. Post-accident care is highly valued at Silverman Chiropractic and with the best medical professionals each person will get personalized aftercare.

Silverman Chiropractic and Rehabilitation takes on a board certified pain management doctor

  • Locations in South Florida
  • Best Chiropractic in South Florida

Silverman Chiropractic and Rehabilitation clinic adds a board certified pain management doctor who specializes in pain management. Post-accident care is highly valued at Silverman Chiropractic and with the best medical professionals each person will get personalized aftercare. To reach peak performance, Mark A Silverman DC’s team will keep those who come to the clinic feeling better long term.

If you have been in a car accident recently and in need of a pain management plan, call Silverman Chiropractic and Rehabilitation and book your appointment. There you will find the chiropractic care that will benefit your life and health. A chiropractic adjustment will get you moving and back to feeling better.

Mark A Silverman DC has locations all over South Florida to ensure each person in the region can have access to chiropractic care. Their locations are located in Miami, 946 SW 82nd Ave, Miami, FL 33144; Hialeah, 709 E 9th St, Hialeah, FL 33010 and Homestead, 46 N Homestead Blvd, Homestead, FL 33030. No matter where you are located, you will be able to find a Mark A Silverman DC office near you.

Mark A Silverman DC’s staff and doctors are professionals with attention to detail. They are attentive to every patient’s needs and make the process stress free. At Mark A Silverman DC office, all questions are answered and patients are kept up to date with information about their results. Not only are they professional but they treat all the patients like family.

###

With over 35 years of chiropractic care excellence, Silverman chiropractic works with the best medical specialist who will provide all patients with personalized post-accident care. On top of our world-class treatments, Mark A Silverman DC chiropractic care knows how important it is that each patient secures competent medical/legal assistance.

Laura Torres

(786)566-2064

Laura@livemediadigital.com

Share article on social media or email:

The Top 25 Healthcare Technology CEOs of Europe for 2020


The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology CEOs of Europe for 2020. As the global COVID-19 pandemic continues to have a profound impact on the healthcare industry, innovative solutions and products have been in high demand. The CEOs recognized this year have met this demand and more, while maintaining their companies’ growth and guiding corporate strategy. Their leadership has produced compelling contributions to the fields of biotechnology, medical devices, healthcare software, as well as other fields.

Notably, several of the CEOs recognized have helped to meet the significant demand for medical devices, testing supplies, and disinfecting agents as a result of the pandemic. For example, Paul Swinney, CEO of Tristel, led his company through a massive uptick in demand for its disinfectant products, and as a result, his company experienced a substantial rise in revenue.

The CEOs and companies that comprise this year’s list have not only sustained their companies’ high performance over many years but have continued to drive growth in an evolving market. A rigorous process was used to evaluate the background of each nominee, and awardees were selected for their expertise, strategic decision-making, innovations in the field, and effective leadership. The Healthcare Technology Report team is excited to highlight the accomplishments of these CEOs.

Christophe Weber (Shire – Takeda), Edward Breen (Danisco – DuPont), Jean-Christophe Tellier (UCB), Enrico Vita (Amplifon), Ester Baiget (Novozymes), Joacim Lindoff (Arjo), Damien McDonald (LivaNova), Britta Fuenfstueck (Hartmann Group), Werner Lanthaler (Evotec), Stefan Vilsmeier (Brainlab), Jakob Just-Bomholt (3Shape), Giorgio Moretti (Dedalus), Lee Morley (EUSA Pharma), Simon Michel (Ypsomed Holding), Gordon Sanghera (Oxford Nanopore Technologies), Tomas Blomquist (Biotage), Patrice Taisson (Softway Medical), Deborah Kobewka (Evaluate, Ltd.), Mariusz Gralewski (DocPlanner), Arndt Rolfs (Centogene), Chris Meredith (Advanced Medical Solutions Group), Paul Swinney (Tristel), Carlos Buesa (Oryzon Genomics), Valentin Kahl and Roman Zantl (ibidi GmbH), Mark Quick (Consort Medical).

Congratulations to each of this year’s awardees. The complete article can be viewed at http://www.thehealthcaretechnologyreport.com

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers and media professionals highly knowledgeable on healthcare technology and the various companies, executives and investors that make up the sector.

Share article on social media or email:

Novalgen licenses mAbsolve’s QumAb™ technology to improve the safety of therapeutic antibodies


Picture of an antibody

Antibody structure

The QumAb technology represents a significant advance and will help NovalGen develop life changing therapeutics for a range of disorders with unmet clinical need.

A new generation of antibody variant developed by mAbsolve has been licensed to Novalgen for evaluation in their pipeline of therapeutic antibodies for treatment of cancer, leukaemias and cardiovascular disease.

QumAb™ is a small variation to the natural antibody structure which eliminates the unwanted inflammatory responses often associated with antibody therapy. In some situations, these responses are beneficial, but often they lead to unpleasant, even dangerous side-effects.

Previous work met with some success, and today about 50% of therapeutic antibodies in development include some sort of alteration to mitigate unwanted side-effects. However, these approaches do not solve the problem completely. QumAb builds on this previous work to provide a complete Fc-silencing solution with excellent manufacturability properties.

Dr Ian Wilkinson, inventor of the QumAb technology, said: “After working with numerous pharma and biotech companies using the earlier methods with limited success, I became convinced that a better solution was possible. I went back to first principles to design and screen a large panel of variants from which QumAb was discovered. I am delighted that in such a short time the new technology is being taken into commercial development.”

Prof Geoff Hale, CEO of mAbsolve, said: “I have devoted my career to the development of therapeutic antibodies, and while we saw some success, many promising antibody drugs were discarded because of unacceptable levels of inflammatory response. QumAb is the best solution to this problem that I have seen and I am thrilled to be working with Novalgen as the first adopter of this new technology.”

Mr Nilesh Modi, COO of Novalgen, said: “I’m delighted to be working with the newly formed mAbsolve team, who individually have fantastic track records. Licensing the QumAb antibody silencing solution will add to our array of technologies and we hope will help us develop safer antibody therapies, and will deliver the life-changing treatments that many patients desperately need..”

Prof Amit Nathwani, CEO and Founder of Novalgen. Professor of Haematology, University College London said: “The QumAb technology represents a significant advance and will help NovalGen develop life changing therapeutics for a range of disorders with unmet clinical need. We are excited to be working in partnership with mAbsolve.”

Prof Kerry Chester, Chief Scientific Officer of Novalgen and Professor of Molecular Medicine, University College London said: “We are thrilled to be early adopters of the QumAb Fc-silencing technology. I have every confidence in the mAbsolve team and believe that QumAb technology will be a critical part of new antibody-based therapies.”

Share article on social media or email:

Yoga Pose Launches 99 Cent Yoga


News Image

Gain access to a library of yoga classes led by certified yoga instructors from around the world, all for just 99 cents per class.

By offering full courses for 99 cents and with no subscription required, we are sharing quality yoga classes at an affordable price.

Yogapose.com, a leader in yoga pose tutorials searchable by symptoms, has just launched 99 Cent Yoga. These subscription-free yoga classes are available for only 99 cents per class, and individuals can pay-per practice.

The yoga classes feature certified yoga instructors that teach yoga at a variety of difficulty levels. Individuals can find the yoga classes that they enjoy and view new classes each week. Individuals only pay for the classes that they take, which are all led by notable, certified yoga instructors from around the globe.

10% of all proceeds from the 99 Cent Yoga classes are donated to Mental Health America.

“By offering full courses for 99 cents and with no subscription required, we are sharing quality yoga classes at an affordable price,” said Cobb Rogers, Co-Founder of Yoga Pose. “We understand the importance of maintaining mental health through yoga and are excited to share this practice with wider audiences than ever before.”

As a form of holistic healing, yogapose.com utilizes yoga as a form of alternative medicine to help or ease the symptoms of both mental and physical illnesses. Additionally, the yogapose.com website is a supportive environment for those researching yoga and wellness. The website features a mix of daily inspirational and informational content that is written from both personal experiences and based on medical research, providing the most credible and accessible yoga-centric content on the web.

Unlike other yoga and wellness publications, yogapose.com works with esteemed yoga professionals and medical experts to create research-based, informational content that the yoga community can trust.

To learn more about yogapose.com and 99 Cent Yoga classes, please visit https://yogapose.com/99-cent-yoga.

About Yoga Pose

YogaPose.com is an entirely free online yoga resource created by Cindy and Cobb Rogers focused on ailment relief through individual yoga poses. The website features a comprehensive library of yoga pose tutorials, all searchable by symptoms, that showcase the physical and mental benefits of each pose. http://www.yogapose.com

Share article on social media or email:

GOLO Expands Into Las Vegas, NV, Creating New Jobs and Donating to Local Non-Profit, Big Brothers Big Sisters of Southern Nevada


GOLO LLC, a weight loss and wellness solution company, is proud to officially announce the opening of their new distribution center at 1660 Helm Drive in Las Vegas, NV. With over 1 million customers worldwide, the Las Vegas facility is a strategic part of the company’s growth plan and specifically helps service U.S. customers on the west coast. With U.S. unemployment around 8% nationwide (National Bureau of Labor Statistics-August 2020), GOLO is proud to be bringing new jobs and opportunities to Las Vegas. GOLO has also committed to donating $100,000 over the next 12 months to charitable organizations that promote a diverse and inclusive society that is free from racism, bias, and injustice. Their first donation of $5,000 went to Big Brothers Big Sisters of Southern Nevada.

GOLO is a company dedicated to healthy living with innovative products to support weight-loss, immunity, and a healthy lifestyle. Developed by a team of expert scientists and medical doctors, The GOLO for Life® plan is an all-natural, plant-based supplement and meal plan, designed to address the root cause of weight gain, Insulin Resistance. GOLO’s Release® supplement is a patented, natural, plant, and mineral-based dietary supplement that is made in the USA. The Release® supplement balances the hormones that regulate fat and carbohydrate metabolism, control stress, cravings and hunger between meals, and overall metabolic health. Release® is paired with the GOLO for Life® meal plan, a simple eating guide to balanced meals, and good nutrition for anyone. Further, GOLO recently launched The AeroTrainer™ exercise platform, an inflatable fitness tool that provides quick, easy, home-based workouts.

GOLO for Wellness, GOLO for Immunity, GOLO for Weight Loss, GOLO for LIFE®.

About GOLO: GOLO is committed to providing individuals with the knowledge of health and wellness, and the power to take back control of their weight and their lives. The GOLO for Life® plan is an all-natural, plant-based supplement and meal plan, designed to address the root cause of weight gain. The GOLO® products provide a safe solution to weight-loss and wellness while helping individuals transition to a healthier and sustainable lifestyle. The developers of GOLO, LLC include a team of dedicated doctors, pharmacists, and researchers. GOLO has reached over a million people worldwide who now have a chance at healthy, sustainable, and affordable weight loss. For more information about the GOLO for Life® plan, visit http://www.golo.com or call 800-730-4656 (GOLO).

Share article on social media or email:

HighOnLove’s Luxurious Line of CBD Wellness Products Available at Urban Outfitters In October 2020


News Image

HighOnLove™, the luxurious line of superior grade lubricating oil blends, is excited to announce that a curated selection of products will be available on Urban Outfitters online. Crafted with luxurious blends of premium grade cannabis seed and essential oils, HighOnLove’s products reflect the highest principals and cosmetic standards set forth by its creator, Angela Mustone. Urban Outfitters’ decision to offer these romantic cannabis-seed products on their site shows how society is breaking free from outmoded myths and stereotypes.

Curated by Angela Mustone, a specialist producer of adult cosmetics, HighOnLove oil blends are transforming romance, bringing a new level of sensuality to skin care, reshaping intimacy, and spoiling everyone it touches, because you deserve nothing but the best.

Angela has travelled extensively across many continents to test ingredients for her groundbreaking product line. Influenced by the world’s premium cosmeticians, these skin-friendly formulas provide revolutionary intimate experiences and a level of romance only cannabis oil can provide.

The Urban Outfitters website will offer a selection of HighOnLove Products including:

  • Dark Chocolate Body Paint: The art of play and making love takes a new meaning with HighOnLove Chocolate Body Paint. Designed as an aphrodisiac in itself, this luscious and rich dark chocolate is made with premium grade hemp seed oil giving couples a satisfying taste for more. The effects of the Chocolate Body Paint take intimacy to a whole other level by releasing euphoric sensations and pure delight. Inspired by the distinguished chocolatiers in Brussels!
  • Sensual Massage Candle: Turn up the heat and set the mood for a sensual massage with the luxurious, soy-based Sensual Massage Candle, blended with nourishing cannabis seed oil and coconut oil. The alluring scent of rose bud seduces your senses, while the sensation of warm oils against your skin encourages relaxation, loving exploration, and romance.
  • Stimulating Sensual Oil: A sensuous fusion of all-natural oils and premium grade hemp seed oil made to revolutionize the way you love by igniting a more intense and profound orgasmic experience. This exhilarating blend can increase the blood flow, promote the production of natural lubricants and ultimately awaken the senses that will take you to uncharted territories. This Stimulating Oil is designed to be transformative for those experiencing vaginal dryness, discomfort, and a decreased libido.
  • Lip Gloss for Couples: Combining sexy and pleasure, HighOnLove’s lip gloss was designed to plump and hydrate the lips making it feel irresistibly kissable while enhancing foreplay by increasing sensitivity and exciting the intimate areas. Thoughtfully created for women and blissfully appreciated by couples.

HighOnLove products are gynecologically tested, chemical-free, vegan, and cruelty free. Made in Canada with premium, 100% natural ingredients, HighOnLove products contain no soap, parabens, allergens or colorants. Made in small batches to guarantee the highest quality. HighOnLove will be available on UrbanOutfitters.com starting October 2020. For more information please visit http://www.highonlove.ca

Share article on social media or email:

Wearable Ozone Gas Sensor with Real Time Monitoring of Personal Exposure to Ozone by AerNos


Ozone Gas Detector by AerNos AerBand

Ozone Gas Detector by AerNos

AerBand Research is a breakthrough that will lead to better answers to the most urgent questions – what pollutants are we exposed too, what matters and how do we avoid them.

AerNos, an innovator in nano gas sensors, is now shipping a game-changing wearable device for air pollution detection and research first showcased during CES 2018 on Good Morning America’s CES coverage. Called AerBand Research, the wearable or clip-able device will revolutionize how scientific studies track and study human exposure to harmful air pollutants.

Scientists, physicians and researchers have long been aware of the connection between air pollution and human health but have been stifled by current air quality monitoring capabilities. AerNos has leveraged advances in nanotechnology, engineering and data science to develop a low-cost nano gas sensor able to detect multiple gases simultaneously to parts-per-billion levels. This will enable scientists, for the first time, to monitor 24/7 individual exposures to toxic gases in research and enable consumers to take steps to reduce or avoid exposures and the health impacts that come with exposure.

According to the Environmental Protection Agency (EPA), ground level Ozone in the air we breathe can harm our health. People most at risk from breathing air containing ozone include people with asthma, children, older adults, and people who are active outdoors, especially outdoor workers. In addition, people with certain genetic characteristics, and people with reduced intake of certain nutrients, such as vitamins C and E, are at greater risk from ozone exposure.

Breathing Ozone can trigger a variety of health problems including chest pain, coughing, throat irritation, and airway inflammation. It also can reduce lung function and harm lung tissue. Ozone can worsen bronchitis, emphysema, and asthma, leading to increased medical care. Ozone exposure has been associated with increase emergency room visits, years of life lost and premature deaths.

“AerBand Research is a breakthrough that will lead to better answers to the most urgent questions I’m hearing from parents everyday – what pollutants are we exposed too, what matters and how do we avoid them,” said Christopher Gavigan, Founder and CEO of Prima, Co-Founder of The Honest Company and AerNos Advisor. “Air pollution monitoring today does not tell me what I’m breathing right here, right now. It significantly limits health research and our ability to take action. AerBand is about to change that.”

AerBand Research is designed to be worn or attached via clip for always-on air pollution monitoring. AerNos’ nano gas sensor technology enables simultaneous detection of multiple indoor and outdoor airborne toxins to ppb levels. AerBand pairs with an end user App for tracking real-time pollution levels, historical information and for accessing recommended actions. Organizations access data via the AerBand Data Cloud website – including detailed air pollution readings from multiple research participants.

“For the first time ever, the world of researchers will be able to monitor 24/7 personal exposure to Ozone and correlate its impact on health and wellness,” said Sundip R. Doshi, Chairman & CEO of AerNos, Inc. “Utilizing AerNos’ AerN2S Technology, our ability to design, developed and manufacture millions of tiny gas sensing elements will enable AerNos and its product partners to bring to the market meaningful gas monitoring solutions.”

In addition Ground Level Ozone’s impact on human health, Ozone affects sensitive vegetation and ecosystems, including forests, parks, wildlife refuges and wilderness areas. Ozone can especially cause damage during the growing season. According to the EPA and other experts, the effects of ozone can then have negative impacts on ecosystems, including loss of species diversity (less variety of plants, animals, insects, and fish), changes to the specific assortment of plants present in a forest, changes to habitat quality, changes to water and nutrient cycles. Furthermore, reducing ground-level ozone can have the following positive impacts on vegetation including protecting forest communities and Improving yields for timber and some crops, such as soybeans and winter wheat.

About AerBand Research, Pricing & Availability

AerBand™ Research is a portable product designed to detect airborne toxins to the parts-per-billion for universities, institutions and organizations conducting research related to the impact of air pollution on health and wellness. AerBand Research for ground level ozone detection is not a consumer product and is meant for research purpose only. For a limited time, AerBand Research for Ozone gas detection is being offered at an introductory price of $562 per unit which includes AerNos Cloud Data Platform access for researchers to download data and other analytics from multiple units that are deployed. Qualified research organizations may learn more about AerBand and purchase AerBand Research for Ozone gas detector directly from AerNos by visiting https://www.aernos.com/aerband-research/.

About AerNos

AerNos, Inc. develops application-specific nano gas sensors based on its breakthrough and proprietary AerN2S™ Technology to detect harmful gases in the environment. AerNos nano gas sensors are designed to be easily integrated into consumer and commercial product lines, such as standalone monitoring devices, non-stationary devices (e.g., drones, industrial robots, construction equipment), modes of transportation, wearables, smartphones, and IoT. For more information, please visit http://www.AerNos.com. You may also contact us at media@aernos.com.

Share article on social media or email:

INDIGO’s Preclinical Animal Model Platform Expands Zebrafish Offering


News Image

With animal studies required by the FDA, selecting the animal model pre-trial that provides the most representative human-surrogate is critical to assessing a potential drug’s likelihood of unwanted effects.

INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust portfolio of in vitro animal model assays with three additional first-in-class zebrafish model systems. Previously available only as a live-model system, INDIGO’s expansion of in vitro zebrafish assays provides scientists the ability to determine whether zebrafish are the appropriate model system for their research prior to investing in costly animal studies, as well as allowing for specific receptor testing post-trial.

“We are dedicated to expanding the offerings available to our customers and believe our zebrafish assays will help researchers confidently take the next step in developments,” says Dr. Jack Vanden Heuvel, Chief Scientific Officer of INDIGO. “This addition gives discovery scientists the ability to make key determinations on the correct animal model for their research with an ortholog that was not previously available before entering animal trials.”

Zebrafish have become a popular model system for developmental and biological research, as well as environmental toxicology, as their easy maintenance, high reproduction rate, and transparent appearance makes them highly versatile. As most compounds can easily penetrate the skin of the zebrafish, drug and toxicological screenings are able to be performed simply by adding these test compounds to their water. For researchers looking at nuclear receptor activity, zebrafish provide an attractive model as nearly all of the 48 human nuclear receptors are also present in the animal model.

In vitro assays, such as those offered by INDIGO, provide important early indications of a compound’s potential for downstream concerns. With animal studies required by the FDA, selecting the animal model that provides the most representative human-surrogate is critical to assessing a potential drug’s likelihood of unwanted effects. Cell-based assay models are crucial to help make this determination prior to entering ADMET studies. In addition, while zebrafish present an ideal model for determining whether an off-target effect occurs, whole model testing is unable to provide information on which specific receptors are affected. INDIGO’s assays allow researchers to definitively determine what receptors are affected, a key piece of information necessary to proceed with development.

INDIGO’s expanded portfolio of zebrafish reporter assays now includes the Androgen Receptor (AR), Aryl Hydrocarbon Receptor (AhR), Estrogen Receptor Alpha (ERa), Glucocortioid Receptor (GR), Peroxisome Proliferator-Activated Receptor Gamma (PPARg), Retinoic Acid Receptor Alpha isoform A (RARaA), and Thyroid Receptor Beta (TRb). Each is available both as a screening service or as an all-inclusive assay kit.

About INDIGO Biosciences, Inc.

INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and in vitro toxicology solutions that accelerate scientific decision-making. INDIGO supplements the world’s largest portfolio of nuclear receptor kits and services and in vitro toxicology solutions with greater results readability, reproducibility, and faster turnaround times. Our solutions, plus supportive team and reliable science and platforms aim to reduce the time, cost, and risk associated with the discovery process. Learn more at http://www.indigobiosciences.com.

Share article on social media or email:

Study of 400 Seniors with COVID-19 Shows High-Touch Primary Care With Early Cardiovascular Risk Factor Modification Can Reduce Disease Mortality by 40 Percent


ChenMed logo

Primary care doctors can use preventive care to reduce coronavirus mortality rates for seniors with underlying health challenges by as much as 40 percent.

ChenMed and University of Miami researchers today announced a new era in predicting hospitalization and severity of coronavirus infections among elderly Medicare patients. Their findings in the October American Journal of Preventive Cardiology also show high-touch primary care with early cardiovascular risk factor modification could explain 40 percent lower mortality among Medicare-eligible seniors due to COVID-19; plus, early stages of cardiovascular disease and socio-economic disadvantage increase the probability of poor outcomes after COVID-19 diagnosis.

Instead of the more than 30 percent mortality rate for such elderly populations with coronavirus infections reported by the United States and Europe during the pandemic, the investigators report just 18 percent mortality among the entire study group of 400 ethnically diverse, low-income, elderly patients in eight states with a mean age of 72 years. For the subset of 244 study patients hospitalized due to COVID-19, the mortality rate was 27 percent.

“We are so grateful to the American Journal of Preventive Cardiology for fast-tracking publication of our peer-reviewed paper,” says lead investigator Reyan Ghany, M.D., FACC, FASE, ChenMed Regional Market Chief Medical Officer and National Director of Cardiovascular Diseases. “For many months, coronavirus infection mortality rates among elderly patients in the United States and Europe have exceeded 30 percent. We’ve now shown how primary care doctors can use preventive care to reduce coronavirus mortality rates for seniors with underlying health challenges by as much as 40 percent. This is a big deal, especially because non-invasive echocardiograms also can help doctors predict hospitalization and severity of coronavirus infections among the most-at-risk populations.”

Co-investigator Leonardo Tamariz, M.D., MPH, Professor of Medicine, Division of Population Health and Computational Medicine, University of Miami, explains the study compared electronic health record data for 400 COVID-19 positive patients benefiting from five or more visits with their primary care doctor between January and May of this year. The data was evaluated against demographic, clinical and echocardiographic predictors and analyzed with primary outcomes being hospitalization and the diagnosis of acute respiratory distress syndrome (ARDS); and mortality as secondary outcome.

“The gold standard of frequent primary care doctor visits for at-risk elderly populations being fortified by screening echocardiograms and early cardiovascular risk interventions, is supported by our research,” notes Dr. Tamariz.

“It is great when doctors can use outcomes data to better educate patients – especially those with demographic, clinical and echocardiographic risk factors,” Dr. Tamariz adds. “More trust is earned and more lives can be saved as patients stay hyper vigilant about COVID-19 preventive measures.” Those measures include include staying socially distant, washing hands frequently, wearing a protective mask, and avoiding groups of 10 or more people.

Multiple prior studies have found that patients with severe COVID-19 infections who die have twice the prevalence of cardiovascular risk factors and coronary artery disease than those who do not. The new study conducted at Chen, Dedicated and JenCare Senior Medical Centers in Florida, Georgia, Illinois, Kentucky, Louisiana, Ohio, Pennsylvania, and Virginia, included four types of predictors: socio-economic; clinical; echocardiographic; and treatment to enhance learnings.

Age, gender, race, census based median household income and area deprivation index for place of residence enhanced the socio-economic profile of study participants and it is interesting to note the study group was 73 percent African American (9% Hispanic and 12% non-Hispanic White); 60 percent female; and had median household income of $28,249.

With regards to clinical care considerations, 100 percent of study participants benefit from personalized high-touch primary care made possible by the Medicare Advantage supplemental insurance held by 26.9 million U.S. beneficiaries. The study participants are living with multiple and major health challenges with 60 percent having hypertension; 50 percent having congestive heart failure; 49 percent having diabetes; 34 percent having chronic obstructive pulmonary disease; and 14 percent having coronary artery disease.

The echocardiographic predictors included diastolic dysfunction, ejection fraction and left ventricular hypertrophy, all easily measured with a non-invasive screening echocardiogram.

“What’s so important about our study” notes Daniel McCarter, MD, FAAFP, ChenMed National Director of Primary Care Advancement, is going beyond confirming earlier studies showing that age and underlying conditions predict coronavirus hospitalizations, acute respiratory distress syndrome, and all-cause mortality among older patients.

“We clearly link distinct demographic predictors, clinical predictors, plus left ventricular heart wall thickness measured by screening echocardiogram to both coronavirus hospitalizations, and to life-threatening acute respiratory distress syndrome caused by COVID-19,” explains Dr. McCarter. “Our findings should facilitate more effective preventive efforts.”

About ChenMed

For seniors most in need of care, high-quality health care often is beyond reach. ChenMed brings concierge-style medicine — and better health outcomes — to the neediest populations. ChenMed is a privately owned medical, management and technology company was, in September, named to the Fortune Magazine “2020 Change the World List” for measurable social impact, business results, innovation, and corporate integration.

A hyper growth company and provider of choice for some 20 Medicare Advantage health insurance plans, ChenMed brands include Chen Senior Medical Center, Dedicated Senior Medical Center, and JenCare Senior Medical Center.

Results of ChenMed’s high-touch approach to primary care are impressive, as illustrated in the Modern Healthcare cover story, which reports, “Indeed, ChenMed’s approach has resulted in 50 percent fewer hospital admissions compared with a standard primary-care practice, 28 percent lower per-member costs and significantly higher use of evidence-based medications.” Learn more about the high-growth company, where patients also average 75 percent fewer emergency room visits @ http://www.ChenMed.com.

About University of Miami

A private research university with more than 17,000 students, the University of Miami serves undergraduate and graduate students in more than 180 majors and programs; invests $324 million in research and sponsored programs annually. While the majority of this work is advanced by Miller School of Medicine faculty, University of Miami investigators conduct hundreds of studies in other areas, too, including marine science, engineering, education, and psychology.

Hemp Health One Launches Its Calming CBD Oil for Pets


If you’re like most pet owners, you treat your pet as your family and love them unconditionally. They only deserve the best, right?

Today, Hemp Health One rolls out the latest addition to its lineup of hemp-based health products. Its Calming Pet Oil contains full spectrum hemp extract with botanical herbs like rock rose, cherry plum (pranus cerasifera), star of Bethlehem, and a few others.    

Together these herbs have the ability to lower irritability, minimize stress and tension, and reduce overstimulation to the “fight or flight” response.* Besides herbs, this pet product has organic MCT oil to assist in rapid and easy digestion. One full dropper includes 16.7mg of CBD per ml for a total of 500mg per bottle.

Furthermore, CBD oil has zero additives, colorings, and artificial flavors. The hemp extract is fully tested by third-party labs, showing that it’s free of pesticides and solvents.

Learn more about our Pet Tincture here: https://www.hemphealthone.com/products/calming-pet-oil

Hemp Health One partners with a farm in Colorado that grows the hemp plants without GMOs, and follows organic, sustainable practices. The founders want nothing but the best for their customers, which is why they chose this partnership. Also, as pet owners, they know that animals, like people, experience stress, fear, and anxiety.

And pets often take on the emotions of their owners, which is even more reason to help support your furry companion. This is exactly what the Calming CBD Hemp Oil was created for. It’s a natural plant-based remedy to aid in the well-being of your pet.*

To learn more about Hemp Health One and its other products you can browse their website here:

https://www.hemphealthone.com/

Find out more information about CBD on its blog page here:

https://www.hemphealthone.com/blogs/the-hemp-health-one-blog

Lastly, you can reach out to the company via email at support@hemphealthone.com or give them a call at 1-888-502-0015.

*These products are not intended to diagnose, treat, cure or prevent disease. Yet, they may help you feel better.

Share article on social media or email: